9 recruiting, 3 active not recruiting, 3 terminated, 3 unknown. 11 Phase 2, 4 Phase 1, 2 Not applicable, 1 Phase 3.
Follow Melanoma Metastatic: new trials by email Literature Review of Melanoma Metastatic trials Research Report on Melanoma Metastatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma. Dried chicory roots, Placebo - Melanoma (Skin) Stage IV, Melanoma (Skin Cancer) | Phase 2 | Recruiting | Radboud University Medical Center | 70 | 2026-07-31 | 2026-07-27 |
| A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma Tumour Infiltrating Lymphocytes Adoptive Cell Therapy, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Aldesleukin - Melanoma (Skin Cancer), Melanoma Metastatic | Phase 2 | Not yet recruiting | East Metropolitan Health Service, Australia | 10 | 2026-07-01 | 2026-06-16 |
| Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma Tunlametinib, Pucotenlimab, Hydroxychloroquine (HC) - Melanoma Metastatic, NRAS Mutation | Phase 2 | Recruiting | Sun Yat-sen University | 37 | 2026-04-01 | 2026-08-10 |
| A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. MTT(Multimodal Tumor Thermal Therapy System)- Colorectal Cancer, MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer, MTT(Multimodal Tumor Thermal Therapy System)- Melanoma - Triple Negative Breast Cancer Metastatic, Melanoma Metastatic | Phase 2 | Recruiting | Fudan University | 95 | 2026-03-30 | 2026-07-13 |
| PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor Lung Cancer (NSCLC), Lung Cancer (SCLC) | Not yet recruiting | Peking University Cancer Hospital & Institute | 40 | 2026-02-01 | 2026-03-05 | |
| A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma [225Ac]Ac-A9-3408, [68Ga]Ga-A9T-3202 - Melanoma Metastatic, Uveal Melanoma, Metastatic | Phase 1 | Terminated | Alpha-9 Oncology USA Inc. | 5 | 2025-11-19 | 2026-08-31 |
| NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma NY-ESO-1 TCR redirected autologous T cell product, Low-dose irradiation, Non-myeloablative lymphodepleting chemotherapy - Advanced Melanoma, Melanoma Metastatic | Phase 1 | Recruiting | Centre Hospitalier Universitaire Vaudois | 9 | 2025-03-24 | 2026-05-15 |
| Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma Stereotactic Body Radiotherapy (extracranial) concurrent with Immunotherapy, Immunotherapy alone - Melanoma Metastatic | Phase 2 | Recruiting | Melanoma Institute Australia | 129 | 2025-03-06 | 2026-05-07 |
| Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study Postbiotic, AntiPD1 - Melanoma Metastatic | Not applicable | Recruiting | Azienda Ospedaliera di Perugia | 35 | 2025-02-01 | 2025-07-03 |
| T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma TIL therapy - Melanoma Metastatic | Phase 1 | Recruiting | Inge Marie Svane | 10 | 2024-12-16 | 2025-01-20 |
| Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution) - Melanoma Metastatic, Melanoma of Skin | Phase 1 / Phase 2 | Active not recruiting | BioInvent International AB | 35 | 2024-12-11 | 2026-10-02 |
| Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma Oral Impact® - Melanoma Metastatic, Locally Advanced Melanoma | Not applicable | Recruiting | Fondazione Melanoma Onlus | 20 | 2024-08-01 | 2025-09-17 |
| Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy. PBMC Kinase Activity Profile - Melanoma Metastatic, Melanoma, Skin | Recruiting | Pamgene International B.V. | 196 | 2024-07-12 | 2025-02-28 | |
| Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC) Melanoma Metastatic | Unknown | Centre Hospitalier Universitaire de Besancon | 77 | 2023-03-24 | 2024-09-19 | |
| A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma BCD-217, BCD-100, Placebo - Melanoma, Melanoma (Skin) | Phase 3 | Active not recruiting | Biocad | 270 | 2022-08-02 | 2025-02-27 |
| Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) Pembrolizumab - Melanoma Metastatic, Melanoma Recurrent | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 29 | 2021-12-10 | 2026-01-29 |
| Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma BCD-217, BCD-100, Placebo - Melanoma, Melanoma Metastatic | Phase 2 | Unknown | Biocad | 117 | 2019-07-01 | 2023-02-10 |
| To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. Experimental combination beyond Focal Progression, Pembrolizumab or Nivolumab - Melanoma Metastatic, BRAF V600 Mutation | Phase 2 | Unknown | Intergruppo Melanoma Italiano | 120 | 2018-06-18 | 2021-12-02 |
| Interleukin-2 in Metastatic Melanoma Interleukin-2 - Melanoma Metastatic | Phase 2 | Terminated | Western Regional Medical Center | 8 | 2012-09-01 | 2018-04-05 |
| Dacarbazine and Carmustine in Metastatic Melanoma Dacarbazine, Carmustine, Neulasta - Melanoma Metastatic | Phase 2 | Terminated | Western Regional Medical Center | 1 | 2012-08-01 | 2018-04-04 |
Showing 20 of 21. Sign in to see all of them.
Melanoma (14) · Neoplasm Metastasis (2) · Uveal Melanoma (2) · Abdominal Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Lung Neoplasms (1) · Sarcoma (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (15) · Neoplasms by Site (15) · Skin Diseases (15) · Skin and Connective Tissue Diseases (15) · Neoplasms by Histologic Type (14) · Neoplasms, Germ Cell and Embryonal (14) · Neoplasms, Nerve Tissue (14) · Neuroectodermal Tumors (14) · Neuroendocrine Tumors (14) · Nevi and Melanomas (14) · Skin Neoplasms (14) · Eye Diseases (2) · Eye Neoplasms (2) · Neoplastic Processes (2) · Pathologic Processes (2)
pembrolizumab (3) · Interleukin-2 (2) · Carmustine (1) · Cyclophosphamide (1) · Dacarbazine (1) · Dietary Fiber (1) · Hydroxychloroquine (1) · Immune Checkpoint Inhibitors (1) · Immunotherapy (1) · Ipilimumab (1) · Metastasectomy (1) · Nivolumab (1) · Radiation (1) · Radiosurgery (1) · Solutions (1)
Biocad (2) · Western Regional Medical Center (2) · Alpha-9 Oncology USA Inc. (1) · Azienda Ospedaliera di Perugia (1) · BioInvent International AB (1) · Centre Hospitalier Universitaire Vaudois (1) · Centre Hospitalier Universitaire de Besancon (1) · East Metropolitan Health Service, Australia (1) · Fondazione Melanoma Onlus (1) · Fudan University (1) · Inge Marie Svane (1) · Instituto do Cancer do Estado de São Paulo (1) · Intergruppo Melanoma Italiano (1) · Melanoma Institute Australia (1) · Pamgene International B.V. (1)
Australia (3) · Italy (3) · Belarus (2) · China (2) · Germany (2) · Russia (2) · United States (2) · Brazil (1) · Canada (1) · Denmark (1) · France (1) · India (1) · Netherlands (1) · Spain (1) · Sweden (1)
Jordan Waypa, FNP (2) · Angela Hong (1) · Arina V Zinkina-Orikhan, PhD (1) · Ben Carnley, MBBS (1) · Hongxia Wang, MD (1) · Paola Queirolo, Dr. (1) · Peter Lau, MBBS (1)
PMID 31299988, PMID 37738976, PMID 41120904
2023 (1)